clinical trial · NCT07250737
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc.·—·available
Muscular Disorders, AtrophicMuscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesGenetic Diseases, InbornGenetic Diseases, X-LinkedMuscular Dystrophiesdelpacibart zotadirsen
brief summary
The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
started
—
primary completion
—
completion
—
last updated
Jun 18, 2026
official title
Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol